As we move into 2026, Canadian drug manufacturers will be “walking a tightrope” to address new foreign and domestic drug pricing policies. On the one hand, in May 2025, President Trump began pursuing a “most-favored-nation” pricing policy for US prescription drugs (MFN Policy) to “end global freeloading.” The MFN Policy places pressure on other countries – including Canada – to increase prescription drug prices to better align with the US’s historically higher prices.
On the other hand, Canada is implementing its own new drug pricing policies that place downward pressure on already lower Canadian prices. For example, the Patented Medicine Prices Review Board (PMPRB)’s new drug pricing guidelines took effect on January 1, 2026. The PMPRB’s guidelines benchmark Canadian drug prices against 11 other countries – most notably, excluding the US.
US MFN Policy: Upward international drug pricing pressure
The executive order Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients (the Executive Order) was issued on May 12, 2025. Its stated purpose is to ensure that what American consumers pay for prescription drugs is capped at the amount that consumers pay in “comparably developed nations.” 1
The Executive Order instructed the US Department of Health and Human Services (HHS) to develop MFN price targets and communicate them to pharmaceutical manufacturers. On May 20, 2025, the HHS announced its MFN target expectation for all brand products that do not have generic or biosimilar competition: “the lowest price in an OECD country with a GDP per capita of at least 60 percent of the US GDP per capita.”2 With a 2024 US GDP per capita of approximately $85,809, the MFN Policy could affect countries such as Canada, Australia, and several European countries.3
The US administration has yet to clearly articulate how MFN pricing will be determined. However, steps have been taken to introduce MFN pricing for Americans:
- Investigation into “Foreign Nations Freeloading.” In the spring of 2025, the US Trade Representative held a public consultation regarding practices with “the effect of forcing Americans to pay for a disproportionate amount of global pharmaceutical research and development.” Nearly 60 submissions were received from a variety of stakeholders.4
- Letters to Pharmaceutical Manufacturers. In July of 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining required steps to lower US prescription drug prices to match the lowest price offered in other developed nations. These steps included using trade policy to support manufacturers in raising drug prices internationally if increased revenues abroad are reinvested into lowering prices for US patients.
- GENEROUS Model. In November 2025, the Centers for Medicare & Medicaid Services (CMS) announced the GENErating cost Reductions fOr US Medicaid (GENEROUS) Model. This initiative is described as “bringing [MFN] pricing to Medicaid.” Access to MFN-level prices will be facilitated through CMS-negotiated rebates tied to an MFN net price benchmark. Per the initiative’s Request for Applications from Applicable Manufacturers, the MFN benchmark prices are intended to be the second-lowest manufacturer-reported net price from a basket of eight comparator countries: Canada, the United Kingdom, France, Germany, Italy, Japan, Denmark, and Switzerland. Participation in GENEROUS is voluntary.
The problem between public list prices and confidential net prices
The GENEROUS Model focus on comparative “net” price benchmarking poses a particular quandary. In contrast to public drug list prices, net prices of prescription drugs are highly confidential, subject to negotiated contracts between drug manufacturers and insurers (both public and private). It remains unclear how CMS would access those confidential prices. Public statements issued by Canada to date indicate it expects drug manufacturers to keep their negotiated lower Canadian net prices confidential.5
Differential pricing around the world has historically been managed by confidential net prices. If the MFN Policy succeeds in benchmarking against net prices, this could cause a seismic shift in the practice of comparator/reference drug pricing.
Meanwhile, other US policies look to Canadian prices staying lower
Paradoxically, while the MFN Policy asks countries such as Canada to pay their fair share of global pharmaceutical R&D by increasing drug prices, other US initiatives strive to benefit from Canada’s lower drug prices. Notably, US law on the Importation of Prescription Drugs (US Importation Rule) sets out a process whereby states can submit proposals to the US Food and Drug Administration to import eligible (lower cost) drugs approved by Health Canada.6 No drugs have yet to move from Canada into the US under the US Importation Rule. However, the current administration is seeking ways to further streamline this process.7
New Canadian policies: Downward drug pricing pressure
During this time of global uncertainty, Canadian drug manufacturers must simultaneously navigate a series of new domestic drug pricing policies that are striving for the opposite objective: making drug prices lower.
- PMPRB. Canada has a unique form of drug price regulation under its Patent Act that is specific to patented medicines. The PMPRB monitors for “excessive prices” charged for patented medicines by considering factors such as the prices charged for the same and similar medicines in Canada and other specified countries. The PMPRB’s new drug pricing guidelines took effect on January 1, 2026. The guidelines benchmark Canadian drug prices against the highest international price in 11 other countries: Australia, Belgium, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, and the United Kingdom. Canada’s previous list of seven reference countries, included the US.8 Excluding the US from the PMPRB’s list of comparator countries makes it challenging to reconcile US pressure to increase drug prices in Canada. Exceeding PMPRB price thresholds can result in lengthy investigations, price uncertainty, and financial penalties.
- Pharmacare. Canada recently enacted legislation for the staged implementation of publicly funded, single-payer, universal drug coverage for Canadians.9 Under Canada’s current drug benefit regime, most Canadians receive private drug insurance from their employers, or from the public regimes governed by individual provinces and territories. To date, Pharmacare funding has been limited to contraception and diabetes products, and only certain provinces have agreed to participate. Canada has also been consulting on a list of other essential medicines and a bulk purchasing strategy to further expand Pharmacare coverage with the hopes of negotiating lower drug prices.
This year will be telling in terms of how much the risk of having to align drug prices with the world’s largest drug market pushes drug prices upwards. Domestic drug pricing policies will need to adapt and find flexibilities to preserve access to medicines in this new world of US MFN pricing.
Footnotes
-
The White House, Executive Order: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients (May 12, 2025).
-
US Department of Health and Human Services, News Release: HHS, CMS Set Most-Favored-Nation Pricing Targets to End Global Freeloading on American Patients (May 20, 2025).
-
World Bank Group, GDP per capita (current US$) - OECD members.
-
Office of the Unites States Trade Representative, Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation (2025).
-
Chris Hannay, “U.S. pushes drugmakers to reveal confidential details of contracts with Canada, other countries” The Globe and Mail (November 10, 2025).
-
US Food and Drug Administration, Importation of Prescription Drugs (October 1, 2020).
-
The White House, Executive Order: Lowering Drug Prices by Once Again Putting Americans First (April 15, 2025).
-
Pharma in Brief, Drug Pricing Update: PMPRB releases final price-review Guidelines (July 1, 2025).
-
Pharmacare Act, S.C. 2024, c. 24.